A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Phase 3Recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 1,440 (estimated)
- Start date
- 13 May 2025
- Primary completion
- 26 Jun 2028 (estimated)
- Study completion
- 6 Jan 2031
- Last update posted
- 30 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Ifinatamab deruxtecan Drug
- Docetaxel Drug
- Prednisone Drug
- Rescue Medication Drug
Conditions and primary outcome
- Prostate Cancer
- Prostatic Neoplasms
Primary outcome
Overall Survival (OS) (Up to approximately 36 months); Radiographic Progression Free Survival (rPFS) (Up to approximately 36 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06925737.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06925737 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.